SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Ayoun Alsoud Rami)
 

Search: WFRF:(Ayoun Alsoud Rami) > Model-informed drug...

Model-informed drug discovery and development strategy for the rapid development of anti-tuberculosis drug combinations

Van Wijk, Rob C, 1991- (author)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
Ayoun Alsoud, Rami (author)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
Lennernäs, Hans (author)
Uppsala universitet,Institutionen för farmaci
show more...
Simonsson, Ulrika S H, Professor (author)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
show less...
 (creator_code:org_t)
2020-03-31
2020
English.
In: Applied Sciences. - : MDPI AG. - 1454-5101 .- 2076-3417. ; 10
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • The increasing emergence of drug-resistant tuberculosis requires new effective and safe drug regimens. However, drug discovery and development are challenging, lengthy and costly.The framework of model-informed drug discovery and development (MID3) is proposed to be applied throughout the preclinical to clinical phases to provide an informative prediction of drug exposure and efficacy in humans in order to select novel anti-tuberculosis drug combinations. The MID3 includes pharmacokinetic-pharmacodynamic and quantitative systems pharmacology models, machine learning and artificial intelligence, which integrates all the available knowledge related to disease and the compounds. A translational in vitro-in vivo link throughout modeling and simulation is crucial to optimize the selection of regimens with the highest probability of receiving approval from regulatory authorities. In vitro-in vivo correlation (IVIVC) and physiologically-based pharmacokinetic modeling provide powerful tools to predict pharmacokinetic drug-drug interactions based on preclinical information. Mechanistic or semi-mechanistic pharmacokinetic-pharmacodynamic models have been successfully applied to predict the clinical exposure-response profile for anti-tuberculosis drugs using preclinical data. Potential pharmacodynamic drug-drug interactions can be predicted from in vitro data through IVIVC and pharmacokinetic-pharmacodynamic modeling accounting for translational factors. It is essential for academic and industrial drug developers to collaborate across disciplines to realize the huge potential of MID3.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Keyword

tuberculosis
MID3
pharmacokinetics
pharmacodynamics
drug-drug interactions
in vitro
in vivo
drug development
Pharmacology
Farmakologi

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Find more in SwePub

By the author/editor
Van Wijk, Rob C, ...
Ayoun Alsoud, Ra ...
Lennernäs, Hans
Simonsson, Ulrik ...
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Basic Medicine
and Pharmacology and ...
Articles in the publication
Applied Sciences
By the university
Uppsala University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view